IM Cannabis Corp.
$0.41
▲
11.04%
2026-04-21 07:29:00
imcannabis.com
NCM: IMCC
Explore IM Cannabis Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.13 M
Current Price
$0.41
52W High / Low
$9.7 / $1.75
Stock P/E
—
Book Value
$-0.45
Dividend Yield
—
ROCE
510.44%
ROE
-516.26%
Face Value
—
EPS
$-1.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
—
Beta
2.27
Debt / Equity
-18.96
Current Ratio
0.67
Quick Ratio
0.54
Forward P/E
-0.28
Price / Sales
0.04
Enterprise Value
$15.9 M
EV / EBITDA
-3.49
EV / Revenue
0.29
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 2. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 3. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 4. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
| 5. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
| 6. | BioXcel Therapeutics, Inc. | $1.2 | — | $32.49 M | — | 557.9% | 74.14% | $8.08 / $1.01 | $-4.28 |
| 7. | Talphera, Inc. | $0.78 | — | $40.17 M | — | -52.04% | -1.15% | $1.57 / $0.38 | $0.34 |
Quarterly Results
Figures shown in M / B
| Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 12.7 M | 12.5 M | 13.34 M | 13.88 M |
| Operating Profit | -0.35 M | 0.16 M | -3.52 M | -0.95 M |
| Net Profit | -0.31 M | 0.17 M | -1.01 M | -0.92 M |
| EPS in Rs | -0.05 | 0.03 | -0.16 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 54.73 M | 54.03 M | 48.8 M | 54.34 M |
| Operating Profit | -11.59 M | -10.23 M | -12.18 M | -22.5 M |
| Net Profit | -11.32 M | -10.59 M | -9.5 M | -188.89 M |
| EPS in Rs | -1.82 | -1.7 | -1.53 | -30.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 31.74 M | 39.19 M | 48.81 M | 60.68 M |
| Total Liabilities | 35.35 M | 36.04 M | 35.11 M | 36.88 M |
| Equity | -0.86 M | 5.24 M | 14.47 M | 22.65 M |
| Current Assets | 22.74 M | 23.36 M | 24.27 M | 32.67 M |
| Current Liabilities | 34.01 M | 34.92 M | 32.85 M | 33.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 4.72 M | -1.08 M | -8.07 M | -12.64 M |
| Investing CF | -0.53 M | -0.47 M | -1.18 M | -1.53 M |
| Financing CF | 1.15 M | 3.83 M | 9.42 M | 4.76 M |
| Free CF | 4.7 M | -1.23 M | -8.66 M | -14.2 M |
| Capex | -0.01 M | -0.16 M | -0.58 M | -1.56 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 10.71% | -10.18% | — | — |
| Earnings Growth % | -11.44% | 94.97% | — | — |
| Profit Margin % | -19.59% | -19.46% | -347.64% | — |
| Operating Margin % | -18.94% | -24.95% | -41.42% | — |
| Gross Margin % | 15.64% | 20.17% | 16.86% | — |
| EBITDA Margin % | -15% | -9.73% | -30.84% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-07-12 | 1:0.166667 |
| 2022-11-17 | 1:0.1 |